PRN: Cutting-Edge New Research Indicates That the Core Personalized Medicine Market will be Worth Over $149 Billion by 2020 with a CAGR of 8.74%

17/feb/2016 20.10.26 PR Newswire Turismo Contatta l'autore

Questo comunicato è stato pubblicato più di 1 anno fa. Le informazioni su questa pagina potrebbero non essere attendibili.

Cutting-Edge New Research Indicates That the Core Personalized Medicine Market will be Worth Over $149 Billion by 2020 with a CAGR of 8.74%


DUBLIN, Feb. 17, 2016 /PRNewswire/ --

Research and Markets ( has announced the addition of the "Personalized Medicine, Targeted Therapeutics and Companion Diagnostic Market to 2019 - Strategic Analysis of Industry Trends, Technologies, Participants and Environment" report to their offering.

Cutting-Edge New Research Indicates That the Core Personalized Medicine Market will be Worth Over $149 Billion by 2020 with a CAGR of 8.74%

The total personalised targeted therapeutic market, for all indications, will grow at a CAGR of 6.47% over the next five years. Strong vertical growth in the companion diagnostic segment however will see a CAGR of 23.71% to 2020, mainly coming from oncology, cardiovascular and infectious disease (HIV/HCV) tests. Advancing technologies within the liquid biopsy market is also driving the market and will see strategic growth over the next five years with a CAGR of 20.6%. The two segments of the liquid biopsy market are tumor cell enrichment products and tumor cell detection technologies.

This market is made up of companion diagnostics and targeted therapeutics and is dominated by oncology, cardiovascular and infectious disease targeted treatment and diagnostics. The report Personalized Medicine, Targeted Therapeutics and Companion Diagnostic Market: Strategic Analysis of Industry Trends, Technologies, Participants, and Environment has already been procured by 21 of the top 25 Pharma companies globally. This newly published edition, is a revolutionary insight into the vertical growing market of personalized healthcare globally.

Individualized, targeted or personalized medicine aims to increase the efficacy of therapeutics via genetic testing and companion diagnostics. Personalized therapeutics and associated companion diagnostics are more specific and effective thereby giving pharma/biotech companies a significant advantage to recuperate R&D costs. Personalized medicine reduces the frequency of adverse drug reactions and therefore has a dramatic impact on health economics. Developmental and diagnostic companies benefit from lower discovery and commercialization costs and more specific market subtypes.

Updates on the personalized medicine, targeted therapeutic and companion diagnostic space have been included in this latest edition to include cutting edge material from international conferences, workshops and symposia. 

The personalized medicine (global & USA) market is presented as follows:

- By Company (e.g., Qiagen, AFFYMETRIX, ATOSSA GENETICS, NODALITY, deCode /Amgen, CELERA, MYRIAD) - By Segment (Targeted therapeutics, Companion Diagnostics, Liquid Biopsies) - By Sub-market (Companion diagnostic, targeted cancer therapeutic, medical technology, pharmacogenomics, consumer genomics, molecular diagnostics, liquid biopsy) - By Therapy (Cancer, Cardiovascular, Infectious Disease)

Key Opinion Leaders that contributed to interview questions within the report include:

- Iain D. Miller, PhD, MBA, Founder & CEO, Healthcare Strategies Group

- Stephen Finn, MBBS, PhD, Associate Professor, Cancer Molecular Diagnostic Laboratory, Consultant Histopathologist and Head of Histopathology, St James's Hospital and Trinity College Dublin, Ireland

- Ronald Przygodzki, MD, Director, Genomic Medicine Implementation at U.S. Department of Veterans Affairs, Washington DC

- Elaine Kenny, PhD, Founder, Elda Biotech, Dublin 2, Ireland

- Chad Clark, Co-President and Chief Operating Officer, Precision for Medicine

- Tobias Guennel, PhD, Principal, Biomarker and IVD Analytics, Precision for Medicine

- David Parker, PhD, Vice President, Integrated Market Access, Precision for Medicine

- Deborah Phippard, PhD, Vice President, Research, Precision for Medicine

- Judi Smith, MS, Vice President, In Vitro Diagnostics Regulatory and Quality, Precision for Medicine

A wealth of financial data & business strategy information is provided including:

- Company financials, sales & revenue figures

- Business Model Strategies for Diagnostic, Pharmaceutical and Biotechnology Companies

- Business Model Strategies for Providers. Provider Systems and Academic Medical Centres

- Business Model Strategies for Payers & Governments

- Private and Public Funding and Personalized Medicine Reimbursement

- Revisions to Current Payment Systems and intellectual property

- How to Gain Market Penetration in the EU

- Cost-effectiveness and Business Value of Personalized Medicine

- Therapeutics and Companion Diagnostics (e.g., BRAC Analysis, Oncotype Dx , KRAS Mutations)

- Comprehensive account of company product portfolios & kits

SWOT, Economic & Regulatory Environment specifics include:

- Key strengths, weaknesses and threats influencing leading player position within the market

- Technologies driving the market (e.g., New-Generation Sequencing Technologies, Ultra-High Throughput Sequencing)

- Top fastest growing market segments and emerging opportunities

- Top pharmaceutical companies within the IPM by market share and revenue

- Comprehensive product portfolios, R&D activity and pipeline therapeutics

- M&A activity and future strategies of top personalized medicine pharmacos

- Personalized Medicine Regulation (USA, UK, Germany, France, Spain, Italy)

- CE-marked Personalized Medicine/Diagnostic Tests

- FDA Advances in Personalized Medicine Regulation

Companies Mentioned

- 23andMe

- Abbott Laboratories

- Abbott Molecular Inc.

- Admera Health (GENEWIZ)

- Affymetrix

- Agendia

- Alere

- Amgen

- Astex Pharmaceuticals

- AstraZeneca

- Atossa Genetics

- Becton Dickenson

- bioMerieux

- BristolMyersSquibb

- Cancer Genetics

- Celera (Quest Diagnostics)

- Celldex Therapeutics

- Claritas Genomics

- CuraGen

- Danaher (Leica Biosystems)

- deCode Genetics (Amgen)

- Foundation Medicine

- EDP Biotech

- Eli Lilly

- ELDA BioTech

- Eisai

- Genelex

- GlaxoSmithKline

- Human Longevity Inc (Cypher Genomics)

- HalioDx

- Ikonisys

- Illumina

- InterGenetics

- Johnson & Johnson

- LabCorp

- Life Technologies

- Merck

- MDxHealth

- MolecularMD Corporation

- Monogram Biosciences

- Myriad

- Nodality

- Novartis MDx

- Orion Genomics

- Oxford BioTherapeutics

- NanoString Technologies

- Pfizer

- Qiagen

- Roche Molecular Diagnostics

- Sanofi

- SensiGen

- Siemens Healthcare Diagnostics

- Takeda

- Thermo Fisher Scientific

- Transgenomic

- Ventana (Roche)

- Vermillion (Ciphergen)

- Vertex Pharmaceuticals

For more information visit

Media Contact:

Research and Markets

Laura Wood, Senior Manager

For E.S.T Office Hours Call +1-917-300-0470

For U.S./CAN Toll Free Call +1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907

Fax (outside U.S.): +353-1-481-1716


blog comments powered by Disqus è un servizio offerto da Factotum Srl